Hansa Biopharma AB (publ) (LON:0RC7)

Hansa Biopharma AB Ratios and Metrics

Market cap in millions GBP. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 10, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	343	282	192	107	206	323
Market Cap Growth	115.68%	46.91%	78.87%	-47.81%	-36.28%	-66.17%
Enterprise Value	362	336	221	109	172	242
Last Close Price	3.40	2.69	2.82	2.09	3.91	7.24
PS Ratio	19.13	15.73	15.52	10.25	16.70	116.57
PB Ratio	-50.53	-41.56	-4.51	-8.18	4.28	5.21
P/TBV Ratio	-	-	-	-	4.47	5.42
EV/Sales Ratio	19.81	18.75	17.89	10.41	13.96	87.45
Debt / Equity Ratio	-11.10	-11.10	-1.83	-5.16	1.31	0.05
Net Debt / Equity Ratio	-2.77	-2.77	-1.14	-0.80	-1.17	-1.13
Net Debt / EBITDA Ratio	-0.45	-0.45	-1.07	-0.17	1.23	1.59
Net Debt / FCF Ratio	-0.42	-0.42	-1.00	-0.18	1.39	1.77
Asset Turnover	0.23	0.23	0.19	0.10	0.11	0.03
Inventory Turnover	19.12	19.12	40.53	50.80	63.34	90.74
Quick Ratio	1.93	1.93	2.22	2.57	5.91	5.33
Current Ratio	1.94	1.94	2.29	2.66	6.06	5.50
Return on Equity (ROE)	-	-	-	-382.37%	-89.84%	-54.84%
Return on Assets (ROA)	-33.08%	-33.08%	-43.41%	-36.55%	-26.67%	-27.56%
Return on Capital Employed (ROCE)	-68.90%	-68.90%	-115.90%	-113.50%	-40.50%	-64.10%
Earnings Yield	-12.45%	-15.14%	-30.37%	-60.53%	-23.68%	-13.88%
FCF Yield	-	-15.71%	-25.39%	-55.02%	-19.61%	-12.25%
Buyback Yield / Dilution	-29.23%	-29.23%	-19.59%	-16.95%	-1.01%	-5.45%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.